https://orcid.org/0000-0003-2994-1093
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Background
Protracted labor is associated with an elevated risk of maternal and fetal complications. Results of randomized controlled trials on the efficacy in labor of phloroglucinol (PHL), a pure antispasmodic drug, are uncertain.
Objectives
To evaluate whether PHL is effective in shortening the first stage of labor.
Search strategy
MEDLINE, EMBASE, LILACS, Scopus, ClinicalTrials.gov, and the Cochrane Library were searched from inception to July 2020.
Selection criteria
Randomized controlled trials (RCTs) concerning women with a singleton vertex pregnancy at term who were treated with PHL.
Data collection and analysis
Relevant data were extracted and tabulated. Review Manager 5.3 was used for data analysis. Primary outcome evaluated was the mean reduction of the first stage of labor.
Main results
Five RCTs, including 487 pregnant women, were analyzed. The first stage of labor duration was significantly shorter in the treatment arm compared to the control group [MD−113.21 min (95% CI−119.63,–106.79)]. A significant shortening of the second stage was achieved in the PHL group [MD−11.12 min (95% CI−12.64,–9.75)] while no differences were reported for the third stage.
Conclusions
PHL might represent an effective treatment to shorten the duration of the first and second stage of labor.
Synopsis
A meta‐analysis of 5 trials found that Phloroglucinol favorably impacts on the total duration of the labor in primiparae and multiparae women with a singleton pregnancy.
Author contributions
A.S. and M.M designed the study. A.S. and G.R. searched the literature and extracted the data. G.R. and P.D.F. performed statistical analyses. A.S., G.R., and F.S. wrote the manuscript. G.S. and A.R. critically revised successive drafts of the paper. All authors read and approved the manuscript.
Disclosure statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.